<bill session="117" type="s" number="4633" updated="2023-04-24T20:00:26Z">
  <state datetime="2022-07-27">REFERRED</state>
  <status>
    <introduced datetime="2022-07-27"/>
  </status>
  <introduced datetime="2022-07-27"/>
  <titles>
    <title type="display">A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.</title>
    <title type="official" as="introduced">A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.</title>
  </titles>
  <sponsor bioguide_id="B000944"/>
  <cosponsors>
    <cosponsor bioguide_id="S001184" joined="2022-07-27"/>
  </cosponsors>
  <actions>
    <action datetime="2022-07-27">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-07-27" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Drug therapy"/>
    <term name="Medicaid"/>
    <term name="Mental health"/>
    <term name="Prescription drugs"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2022-11-21T16:19:15Z" status="Introduced in Senate">This bill requires the Centers for Medicare &amp; Medicaid Services to issue guidance for state Medicaid programs on best practices to support individuals with major depressive disorder or other mental health conditions, including options that include pharmacogenetic testing.</summary>
</bill>
